Literature DB >> 24012193

Resistance to targeted therapies: a role for microRNAs?

Cristina Migliore1, Silvia Giordano.   

Abstract

The discovery of oncogene addiction dramatically changed the therapeutic approach for cancer treatment, and many drugs targeting specific molecular alterations are now in clinics. Despite the big success of these new compounds, the main limit to their efficacy is represented by resistance to therapy. The alteration of the activity or of the expression of many proteins has already been linked to the onset of resistance, but recent evidence indicates a role of microRNAs (miRNAs) as well. In this context, the idea of exploiting miRNAs as predictors of response or resistance to cancer therapy represents an intriguing possibility. The purpose of this review is to address the relationship between miRNAs and targeted therapies response and resistance.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  mechanisms of resistance; miRNAs; molecular therapies; sensitivity to therapy

Mesh:

Substances:

Year:  2013        PMID: 24012193     DOI: 10.1016/j.molmed.2013.08.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  17 in total

1.  miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.

Authors:  Marta Díaz-Martínez; Lucía Benito-Jardón; Lola Alonso; Lisa Koetz-Ploch; Eva Hernando; Joaquin Teixidó
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

Review 2.  Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Authors:  Rong-Li Zheng; Yu-Jie Jiang; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state.

Authors:  Nicholas Skiados; Fareesa Aftab; Wen Cai Zhang; Cerena Moreno; Luis Silva; Paul Joshua Anthony Corbilla; John M Asara; Aaron N Hata; Frank J Slack
Journal:  Cancer Gene Ther       Date:  2022-07-15       Impact factor: 5.854

4.  MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.

Authors:  S Jagannathan; N Vad; S Vallabhapurapu; S Vallabhapurapu; K C Anderson; J J Driscoll
Journal:  Leukemia       Date:  2014-09-19       Impact factor: 11.528

Review 5.  Signaling by exosomal microRNAs in cancer.

Authors:  Germana Falcone; Armando Felsani; Igea D'Agnano
Journal:  J Exp Clin Cancer Res       Date:  2015-04-02

6.  Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.

Authors:  Nisebita Sahu; Jean-Philippe Stephan; Darlene Dela Cruz; Mark Merchant; Benjamin Haley; Richard Bourgon; Marie Classon; Jeff Settleman
Journal:  Nat Commun       Date:  2016-08-03       Impact factor: 14.919

7.  Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.

Authors:  Weihua Zhou; Jie Xu; Elise Gelston; Xing Wu; Zhengzhi Zou; Bin Wang; Yunxin Zeng; Hua Wang; Anwen Liu; Lingzhi Xu; Quentin Liu
Journal:  Oncotarget       Date:  2015-08-28

8.  MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52.

Authors:  Zhifen Luo; Xiqing Li; Zunlan Zhao; Xinglong Yang; Shengjun Xiao; Yun Zhou
Journal:  Oncol Lett       Date:  2016-12-27       Impact factor: 2.967

9.  Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells.

Authors:  Duc-Hiep Bach; Donghwa Kim; Song Yi Bae; Won Kyung Kim; Ji-Young Hong; Hye-Jung Lee; Nirmal Rajasekaran; Soonbum Kwon; Yanhua Fan; Thi-Thu-Trang Luu; Young Kee Shin; Jeeyeon Lee; Sang Kook Lee
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-29       Impact factor: 8.886

10.  MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis.

Authors:  Veronika Hruskova; Romana Jandova; Lucia Vernerova; Herman Mann; Ondrej Pecha; Klara Prajzlerova; Karel Pavelka; Jiri Vencovsky; Maria Filkova; Ladislav Senolt
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.